Timing underpins the benefits associated with injectable collagen biomaterial therapy for the treatment of myocardial infarction

Biomaterials

Volumn 39, Issue , 2015, Pages 182-192

  Blackburn, Nick J R ^a,b   Sofrenovic, Tanja ^a,b   Kuraitis, Drew ^a,b   Ahmadi, Ali ^a,b   McNeill, Brian ^a   Deng, Chao ^c   Rayner, Katey J ^a   Zhong, Zhiyuan ^c   Ruel, Marc ^a,b   Suuronen, Erik J ^a,b  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c SOOCHOW UNIVERSITY   (China)

Author keywords

Collagen; Extracellular matrix; Fibrosis; Heart; Hydrogel

Indexed keywords

BIOLOGICAL MATERIALS; BIOMATERIALS; CARDIOLOGY; CELL DEATH; COLLAGEN; ENZYME INHIBITION; HEART; REPAIR;

CLINICAL TRANSLATION; EXTRACELLULAR MATRICES; FIBROSIS; INFLAMMATORY RESPONSE; INJECTABLE HYDROGELS; MYOCARDIAL INFARCTION; THERAPEUTIC EFFECTS; VENTRICULAR REMODELING;

HYDROGELS;

BIOMATERIAL; COLLAGEN; HYDROGEL;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HYDROGEL; MOUSE; NONHUMAN; THERAPY EFFECT; ANIMAL; C57BL MOUSE; CHEMISTRY; ECHOCARDIOGRAPHY; EXTRACELLULAR MATRIX; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MYOCARDIAL INFARCTION; THERAPEUTIC USE;

MUS;

ANIMALS; BIOCOMPATIBLE MATERIALS; COLLAGEN; ECHOCARDIOGRAPHY; EXTRACELLULAR MATRIX; HYDROGEL; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION;

EID: 84919474064     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.11.004     Document Type: Article

References (47)

1. Shah A.M., Mann D.L. In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet 2011, 378:704-712.
2. McMurray J.J.V., Pfeffer M.A. Heart failure. Lancet 2005, 365:1877-1889.
3. Burchfield J.S., Xie M., Hill J.A. Pathological ventricular remodeling: mechanisms: part 1 of 2. Circulation 2013, 128:388-400.
4. Jessup M., Brozena S. Heart failure. NEngl J Med 2003, 348:2007-2018.
5. Kemp C.D., Conte J.V. The pathophysiology of heart failure. Cardiovasc Pathol 2012, 21:365-371.
6. Burdick J.A., Mauck R.L., Gorman J.H., Gorman R.C. Acellular biomaterials: an evolving alternative to cell-based therapies. Sci Transl Med 2013, 5. 176ps4.
7. Johnson T.D., Christman K.L. Injectable hydrogel therapies and their delivery strategies for treating myocardial infarction. Expert Opin Drug Deliv 2013, 10:59-72.
8. Radhakrishnan J., Krishnan U.M., Sethuraman S. Hydrogel based injectable scaffolds for cardiac tissue regeneration. Biotechnol Adv 2014, 32:449-461.
9. Gurtner G.C., Werner S., Barrandon Y., Longaker M.T. Wound repair and regeneration. Nature 2008, 453:314-321.
10. Hwang M.W., Matsumori A., Furukawa Y., Ono K., Okada M., Iwasaki A., et al. Neutralization of interleukin-1beta in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling. JAm Coll Cardiol 2001, 38:1546-1553.
11. Kuraitis D., Giordano C., Ruel M., Musaro A., Suuronen E.J. Exploiting extracellular matrix-stem cell interactions: a review of natural materials for therapeutic muscle regeneration. Biomaterials 2012, 33:428-443.
12. Malliaras K., Kreke M., Marban E. The stuttering progress of cell therapy for heart disease. Clin Pharmacol Ther 2011, 90:532-541.
13. Sanganalmath S.K., Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res 2013, 113:810-834.
14. Surder D., Manka R., Lo Cicero V., Moccetti T., Rufibach K., Soncin S., et al. Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction: effects on global left ventricular function. Circulation 2013, 127:1968-1979.
15. Traverse J.H., Henry T.D., Pepine C.J., Willerson J.T., Ellis S.G. One-year follow-up of intracoronary stem cell delivery on left ventricular function following ST-elevation myocardial infarction. JAm Med Assoc 2014, 311:301-302.
16. Landa N., Miller L., Feinberg M.S., Holbova R., Shachar M., Freeman I., et al. Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation 2008, 117:1388-1396.
17. Ahmadi A., McNeill B., Vulesevic B., Kordos M., Mesana L., Thorn S., et al. The role of integrin alpha2 in cell and matrix therapy that improves perfusion, viability and function of infarcted myocardium. Biomaterials 2014, 35:4749-4758.
18. Kuraitis D., Berardinelli M.G., Suuronen E.J., Musarò A. Anecrotic stimulus is required to maximize matrix-mediated myogenesis in mice. Dis Model Mech 2013, 6:793-801.
19. Kuraitis D., Ebadi D., Zhang P., Rizzuto E., Vulesevic B., Padavan D.T., et al. Injected matrix stimulates myogenesis and regeneration of mouse skeletal muscle after ischaemic injury. Eur Cell Mater 2012, 24:175-195.
20. Takagawa J., Zhang Y., Wong M.L., Sievers R.E., Kapasi N.K., Wang Y., et al. Myocardial infarct size measurement in the mouse chronic infarction model: comparison of area- and length-based approaches. JAppl Phys 2007, 102:2104-2111.
21. Cecchini M.G., Felix R., Fleisch H., Cooper P.H. Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. JBone Miner Res 1987, 2:135-142.
22. Hedayat M., Mahmoudi M.J., Rose N.R., Rezaei N. Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev 2010, 15:543-562.
23. Ramos C.D., Canetti C., Souto J.T., Silva J.S., Hogaboam C.M., Ferreira S.H., et al. MIP-1alpha[CCL3] acting on the CCR1 receptor mediates neutrophil migration in immune inflammation via sequential release of TNF-alpha and LTB4. JLeukoc Biol 2005, 78:167-177.
24. Haberstroh U., Pocock J., Gomez-Guerrero C., Helmchen U., Hamann A., Gutierrez-Ramos J.C., et al. Expression of the chemokines MCP-1/CCL2 and RANTES/CCL5 is differentially regulated by infiltrating inflammatory cells. Kidney Int 2002, 62:1264-1276.
25. Kraaijeveld A.O., de Jager S.C., de Jager W.J., Prakken B.J., McColl S.R., Haspels I., et al. CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms. Circulation 2007, 116:1931-1941.
26. Van Dyken S.J., Locksley R.M. Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Ann Rev Immunol 2013, 31:317-343.
27. Eyman D., Damodarasamy M., Plymate S.R., Reed M.J. CCL5 secreted by senescent aged fibroblasts induces proliferation of prostate epithelial cells and expression of genes that modulate angiogenesis. JCell Physiol 2009, 220:376-381.
28. Li A.H., Liu P.P., Villarreal F.J., Garcia R.A. Dynamic changes in myocardial matrix and relevance to disease: translational perspectives. Circ Res 2014, 114:916-927.
29. Kadner K., Dobner S., Franz T., Bezuidenhout D., Sirry M.S., Zilla P., et al. The beneficial effects of deferred delivery on the efficiency of hydrogel therapy post myocardial infarction. Biomaterials 2012, 33:2060-2066.
30. Rane A.A., Chuang J.S., Shah A., Hu D.P., Dalton N.D., Gu Y., et al. Increased infarct wall thickness by a bio-inert material is insufficient to prevent negative left ventricular remodeling after myocardial infarction. PloS One 2011, 6:e21571.
31. Seif-Naraghi S.B., Singelyn J.M., Salvatore M.A., Osborn K.G., Wang J.J., Sampat U., et al. Safety and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction. Sci Transl Med 2013, 5. 173ra25.
32. Dai W., Wold L.E., Dow J.S., Kloner R.A. Thickening of the infarcted wall by collagen injection improves left ventricular function in rats: a novel approach to preserve cardiac function after myocardial infarction. JAm Coll Cardiol 2005, 46:714-719.
33. Eckhouse S.R., Purcell B.P., McGarvey J.R., Lobb D., Logdon C.B., Doviak H., et al. Local hydrogel release of recombinant TIMP-3 attenuates adverse left ventricular remodeling after experimental myocardial infarction. Sci Transl Med 2014, 6. 223ra21.
34. Garbern J.C., Minami E., Stayton P.S., Murry C.E. Delivery of basic fibroblast growth factor with a pH-responsive, injectable hydrogel to improve angiogenesis in infarcted myocardium. Biomaterials 2011, 32:2407-2416.
35. Lin Y.D., Luo C.Y., Hu Y.N., Yeh M.L., Hsueh Y.C., Chang M.Y., et al. Instructive nanofiber scaffolds with VEGF create a microenvironment for arteriogenesis and cardiac repair. Sci Transl Med 2012, 4. 146ra09.
36. Rosso F., Giordano A., Barbarisi M., Barbarisi A. From cell-ECM interactions to tissue engineering. JCell Physiol 2004, 199:174-180.
37. Kloner R.A., Fishbein M.C., Lew H., Maroko P.R., Braunwald E. Mummification of the infarcted myocardium by high dose corticosteroids. Circulation 1978, 57:56-63.
38. Santini M.P., Rosenthal N. Myocardial regenerative properties of macrophage populations and stem cells. JCardiovasc Transl Res 2012, 5:700-712.
39. Aurora A.B., Porrello E.R., Tan W., Mahmoud A.I., Hill J.A., Bassel-Duby R., et al. Macrophages are required for neonatal heart regeneration. JClin Invest 2014, 124:1382-1392.
40. Ramani R., Nilles K., Gibson G., Burkhead B., Mathier M., McNamara D., et al. Tissue inhibitor of metalloproteinase-2 gene delivery ameliorates postinfarction cardiac remodeling. Clin Transl Sci 2011, 4:24-31.
41. Monden Y., Kubota T., Tsutsumi T., Inoue T., Kawano S., Kawamura N., et al. Soluble TNF receptors prevent apoptosis in infiltrating cells and promote ventricular rupture and remodeling after myocardial infarction. Cardiovasc Res 2007, 73:794-805.
42. Virag J.A., Rolle M.L., Reece J., Hardouin S., Feigl E.O., Murry C.E. Fibroblast growth factor-2 regulates myocardial infarct repair: effects on cell proliferation, scar contraction, and ventricular function. Am J Pathol 2007, 171:1431-1440.
43. Bayomy A.F., Bauer M., Qiu Y., Liao R. Regeneration in heart disease-Is ECM the key?. Life Sci 2012, 91:823-827.
44. Dobaczewski M., Gonzalez-Quesada C., Frangogiannis N.G. The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. JMol Cell Cardiol 2010, 48:504-511.
45. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007, 87:1285-1342.
46. McGarvey J.R., Pettaway S., Shuman J.A., Novack C.P., Zellars K.N., Freels P.D., et al. Targeted injection of a biocomposite material alters macrophage and fibroblast phenotype and function following myocardial infarction: relation to left ventricular remodeling. JPharmacol Exp Ther 2014, 350:701-709.
47. Purcell B.P., Lobb D., Charati M.B., Dorsey S.M., Wade R.J., Zellars K.N., et al. Injectable and bioresponsive hydrogels for on-demand matrix metalloproteinase inhibition. Nat Mater 2014, 13:653-661.